MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.…
MediciNova (MNOV) Reports Q3 Loss, Misses Revenue Estimates
MediciNova (NASDAQ: MNOV) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 6 employees.
The shares were at 1.310 USD on 20 November 2026, down 7.7% over 52 weeks. Its 52-week range is 1.220 USD to 3.611 USD: the price is 63.7% below the high and 7.4% above the low.
Its market capitalisation is 67.11M USD.
MediciNova reports return on equity of -28.9% and revenue up 12.4% year over year.
It holds more cash than debt, a net cash position of 29.16M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 19 February 2027.